683:HKEXKerry Properties Limited Analysis
Data as of 2026-03-17 - not real-time
HK$7.77
Latest Price
5/10Risk
Risk Level: Medium
Executive Summary
Green Tea Group is trading at HK$7.77, comfortably above its 20‑day (HK$7.34), 50‑day (HK$7.12) and 200‑day (HK$6.95) simple moving averages, indicating a bullish price trend. The RSI of 61 and a bullish MACD histogram (+0.06) reinforce forward momentum, while the stock sits near its technical support of HK$6.70 and below the near‑term resistance of HK$7.98. Volatility remains high at 38% over the past 30 days, yet beta is exceptionally low (0.07), suggesting price swings are largely company‑specific rather than market‑driven.
Fundamentally, revenue is expanding at a robust 23% YoY with solid gross (38%) and operating (13%) margins, and forward earnings per share are projected to rise to HK$1.03, driving the forward P/E down to 7.6x. The balance sheet shows net cash (cash HK$1.35bn vs debt HK$1.14bn) and positive operating cash flow, though free cash flow is currently flat and ROE/ROA are reported as zero, flagging potential accounting quirks. Analysts’ consensus is a strong buy with a mean target price of HK$11.53, implying roughly 48% upside from the current level.
Given the stark disparity between the DCF‑derived fair value of HK$37.80 and the market price, the stock appears significantly undervalued. The combination of strong growth metrics, modest valuation multiples (P/E 11.3x, P/B 2.6x) and an “Extreme Greed” market sentiment supports a bullish outlook, while the primary risks stem from high volatility, medium regulatory and geographic exposure, and a leveraged balance sheet.
Fundamentally, revenue is expanding at a robust 23% YoY with solid gross (38%) and operating (13%) margins, and forward earnings per share are projected to rise to HK$1.03, driving the forward P/E down to 7.6x. The balance sheet shows net cash (cash HK$1.35bn vs debt HK$1.14bn) and positive operating cash flow, though free cash flow is currently flat and ROE/ROA are reported as zero, flagging potential accounting quirks. Analysts’ consensus is a strong buy with a mean target price of HK$11.53, implying roughly 48% upside from the current level.
Given the stark disparity between the DCF‑derived fair value of HK$37.80 and the market price, the stock appears significantly undervalued. The combination of strong growth metrics, modest valuation multiples (P/E 11.3x, P/B 2.6x) and an “Extreme Greed” market sentiment supports a bullish outlook, while the primary risks stem from high volatility, medium regulatory and geographic exposure, and a leveraged balance sheet.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 7/10
Key Factors
- Price above key moving averages
- Bullish MACD and RSI in the 60s
- Decreasing volume and proximity to resistance
Medium Term
1–3 yearsPositive
Model confidence: 8/10
Key Factors
- 23% revenue growth and expanding margins
- Forward P/E of 7.6x indicating cheap earnings
- Analyst target price suggesting ~48% upside
Long Term
> 3 yearsPositive
Model confidence: 9/10
Key Factors
- DCF fair value far exceeds market price
- Net cash position and strong operating cash flow
- Resilient brand presence in China’s consumer‑cyclical sector
Key Metrics & Analysis
Financial Health
Revenue Growth23.10%
Profit Margin9.59%
P/E Ratio11.3
Debt/Equity65.44
P/B Ratio2.6
Op. Cash FlowHK$1.0B
Technical Analysis
TrendBullish
RSI61.4
SupportHK$6.70
ResistanceHK$7.98
MA 20HK$7.34
MA 50HK$7.12
MA 200HK$6.94
MACDBullish
VolumeDecreasing
Fear & Greed Index79.14
Valuation
Fair ValueHK$37.80
Target PriceHK$11.53
Upside/Downside48.34%
GradeUndervalued
TypeGrowth
Risk Assessment
Beta0.07
Volatility37.77%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.